Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.

Conditions:   Obesity;   OverweightIntervention:   Drug: Alli® 60 mgSponsors:   GlaxoSmithKline;   CRO: Hamell, The Loft, 1A Salcott Road, London SW11 6DQNot yet recruiting - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials